ARX FY26 Preliminary Results

• Total revenue of NZ$104 million, exceeding guidance
• Normalised EBITDA of NZ$11-12 million, exceeding guidance
• Positive net cash flow of NZ$5 million

Aroa Biosurgery Limited (ASX: ARX) has announced preliminary unaudited result highlights for the year ended 31 March 2026. The company reported total revenue of NZ$104 million on an actual basis (NZ$101 million constant currency), exceeding its FY26 guidance of NZ$92-100 million (constant currency). This performance reflects stronger than anticipated sales in the Myriad® portfolio, with growth of 52% (constant currency) on FY25 sales. Normalised EBITDA is likely to be in the range of NZ$11-12 million on an actual basis (NZ$10-$11 million constant currency), which primarily reflects the increased level of revenue. The company also reported positive net cash flow of NZ$5 million and a cash balance of NZ$27 million at 31 March 2026, up from NZ$23 million at 30 Sept 2025. CEO Brian Ward stated, 'We are delighted with the strong performance reflected in these preliminary results, driven by continued growth in the Myriad portfolio. We look forward to providing further details on the release of our audited full year results at the end of May'.

The company expects total revenue of approximately NZ$104 million on an actual basis (NZ$101 million constant currency), representing growth of 21% (constant currency) on FY25 results. Normalised EBITDA is likely to be in the range of NZ$11-12 million on an actual basis (NZ$10-$11 million constant currency).